Selective decontamination of the digestive tract and oropharynx: after 30 years of debate is the definitive answer in sight?

Current Opinion in Critical Care
Richard J PriceSuDDICU Collaboration

Abstract

Selective digestive or oropharyngeal decontamination has been being used as a means to prevent infections and death in intensive care patients for the past 30 years. It remains controversial and its use is limited. In this review, we summarize the recently published data on efficacy of selective decontamination and effects on antibiotic resistances. The most recent meta-analysis shows a reduced mortality when selective digestive or oropharyngeal decontamination are compared with either standard care or oropharyngeal chlorhexidine. Selective decontamination is associated with reduced bacteraemia, and although this effect is greater with selective digestive decontamination compared with selective oropharyngeal decontamination, there is not a mortality difference between these two interventions. Reanalysis of infection data suggests, however, that selective decontamination may also have effects on concurrent control groups. Current evidence generally shows that antibiotic resistance is decreased although much of these data come from the Netherlands (an area with low endemic antibiotic resistance rates). There are currently two huge cluster randomized clinical trials, one in early recruitment, one in development, which will hopeful...Continue Reading

References

Dec 31, 1997·American Journal of Respiratory and Critical Care Medicine·M Garrouste-OrgeasB Schlemmer
Jan 2, 2009·The New England Journal of Medicine·A M G A de SmetM J M Bonten
Dec 8, 2009·American Journal of Respiratory and Critical Care Medicine·Evelien A N OostdijkMarc J M Bonten
Mar 17, 2010·Intensive Care Medicine·Robin F BenusTjip S van der Werf
Feb 2, 2011·Critical Care Medicine·Evelien A N OostdijkUNKNOWN Dutch SOD-SDD Trialists Group
May 31, 2012·The Journal of Antimicrobial Chemotherapy·Evelien A N OostdijkUNKNOWN Dutch SOD-SDD Trialists Group
Jul 19, 2012·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·Andy PetrosHendrick van Saene
Jan 29, 2013·The Lancet Infectious Diseases·Nick DanemanUNKNOWN SuDDICU Canadian Study Group
May 18, 2013·Australian Critical Care : Official Journal of the Confederation of Australian Critical Care Nurses·Stephan U DombrowskiUNKNOWN SuDDICU UK Study Group
Jul 3, 2013·American Journal of Respiratory and Critical Care Medicine·Evelien A N OostdijkUNKNOWN Dutch SOD-SDD trialists group
Apr 9, 2014·The Journal of Antimicrobial Chemotherapy·Elena BuelowWillem van Schaik
May 16, 2014·British Journal of Anaesthesia·R R CanterUNKNOWN Selective Decontamination of the Digestive tract in critically ill patients treated in Intensive Care Unit (SuDDICU) Investi
Oct 2, 2014·JAMA : the Journal of the American Medical Association·Evelien A N OostdijkMarc J M Bonten
Apr 17, 2015·Critical Care : the Official Journal of the Critical Care Forum·Bastiaan H J WittekampMarc J M Bonten
Jun 25, 2015·Critical Care : the Official Journal of the Critical Care Forum·Nienke L Plantinga, Marc J M Bonten

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02208154
NCT02389036

Related Concepts

Related Feeds

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.